To report the early development of epiretinal membranes (ERM) in eyes with retinal vein occlusions (RVO) treated with intravitreal bevacizumab and to describe possible mechanisms that may be involved in the growth and contraction of these lesions. Methods Retrospective and interventional study that included 25 eyes of 25 patients with RVO (16 eyes with central retinal vein occlusion and nine eyes with branch retinal vein occlusion). After an initial 2.5 mg/0.1 ml intravitreal bevacizumab injection all patients were followed-up every 6 weeks. Re-treatments were based on visual acuity and optical coherence tomography findings.
INTRODUCTION
Retinal vein occlusion (RVO) is a vascular disease that can be subdivided into central retinal vein occlusions (CRVO) and branch retinal vein occlusions (BRVO). Both diseases are associated with an upregulation of vascular endothelial growth factor (VEGF) mRNA and with increased intraocular levels of VEGF, especially in those where neovascularisation is present. 1 The presence of macular oedema in patients with RVO has also been associated with higher levels of VEGF and retinal ischaemia. Inhibiting the effect of VEGF would be a rational therapy to reduce macular oedema and retinal ischaemia, and to prevent neovascularisation in eyes with RVO. Bevacizumab (Avastin, Genentech, Inc., San Francisco, California, USA) is a full-length humanised monoclonal nonselective antibody against VEGF approved by the Food and Drug Administration for the treatment of metastatic colorectal cancer in combination with chemotherapy. Since the first report of a patient with CRVO treated with intravitreal bevacizumab by Rosenfeld et al, 2 several studies have described functional and anatomical improvement in patients affected with RVO treated with this anti-VEGF therapy. 3e6 This novel therapy seems to be well tolerated even after numerous re-treatments. However, a rebound of macular oedema associated with deterioration of visual acuity has been described and an increase of retinal ischaemia in a patient with CRVO has been reported in relation to the administration of intravitreal bevacizumab. 7 8 The purpose of this study is to describe the early onset of secondary epiretinal membrane (ERM) in eyes with RVO treated with intravitreal bevacizumab.
MATERIAL AND METHODS
A retrospective, interventional and non-comparative case series study was conducted. Patients with CRVO or BRVO were offered treatment with an intravitreal injection of bevacizumab. Evaluation with best corrected visual acuity (BCVA) with Snellen charts, non-contact intraocular pressure measurement, slit lamp examination of the anterior segment, exploration of the fundus by biomicroscopy and macular thickness measurement using optical coherence tomography (OCT; OCT Stratus, Carl Zeiss Meditec, Dublin, California, USA) was done at baseline and thereafter approximately every 6 weeks. In eight patients a fluorescein angiography was performed at baseline. All patients with previous therapy for RVO (ie, laser photocoagulation, intravitreal triamcinolone) and/or intraocular surgery within the previous 6 months, patients with history of uveitis or other pathologies that may affect the macula (ie, diabetic retinopathy) were excluded from this study.
Each dose of 2.5 mg/0.1 ml bevacizumab was prepared in the pharmacy of the hospital under sterile conditions and administered as an intravitreal injection in theatre. All patients received topical chloramphenicol 0.5% four times a day for 3 days after the injection.
A positive response to intravitreal bevacizumab was normally assumed if there was an increase in BCVA of 2 or more Snellen lines together with a decrease equal or greater than 100 mm of central macular thickness. Retreatment criteria was at discretion of the specialist, but generally it was indicated if: (1) after an initial positive response there was persistent intra-or subretinal fluid; (2) after an initial positive response there was a decrease of 2 or more BCVA lines with or without increase of central macular thickness; (3) there was absence of positive response to the initial injection. In those patients that showed no positive response after two consecutive treatments, the administration of further bevacizumab injections was discontinued.
The diagnosis of ERM was established by biomicroscopy and by an OCT image showing the presence of a highly reflective layer on the inner retinal surface at the macular area.
For the statistical analysis, BCVA was converted into logarithm of the minimum angle of resolution (logMAR) units. All continuous variables are expressed as mean6SD. Serial changes in BCVA and macular thickness were compared with Wilcoxon paired test. All data were analysed with SPSS V.13.0. A p value <0.05 was considered to be significant.
RESULTS
Twenty-five eyes of 25 patients, 14 male and 11 female, were included in this study. In 16 eyes (64%) there was a diagnosis of CRVO, while nine eyes (36%) were diagnosed as having BRVO. Mean age at baseline was 64614 (range 38e84) years.
Before intravitreal bevacizumab, in the group of patients with BRVO, two eyes had been treated with argon laser macular grid photocoagulation, one eye with intravitreal triamcinolone acetonide (IVTA) and two eyes with IVTA and grid laser. In the group of patients with CRVO, two of them had one previous IVTA injection and one patient received argon laser panretinal photocoagulation. All these treatments were administered at least 6 months before the bevacizumab injection.
Patients were followed for 8.363.3 (range 4.5e13.5) months. The mean time period between the beginning of the symptoms related to RVO and the administration of bevacizumab was 15624 (range 0.5e97.5) months. Eleven patients were treated with a single initial injection, eight patients with two injections and six patients with three injections, resulting in an average of 1.8 injections per eye.
At baseline, mean BCVA was 1.0060.57 logMAR and an improvement in BCVA was observed throughout the follow-up. The increase in BCVA was statistically significant compared with baseline and follow-up visits at weeks 6, 12, 30, 36 and 54 (table 1) .
Mean initial central macular thickness measured with OCT was 4636204 mm and a statistically significant decreased was observed at weeks 6, 12, 24, 30, 36 and 54. In the subgroup analysis, patients with BRVO showed an initial mean BCVA of 0.6760.38 logMAR and central retinal thickness of 3476133 mm. During follow-up, there were no statistically significant differences in these two variables compared with baseline. Patients with CRVO showed an initial mean BCVA of 1.1860.58 logMAR and a significant increase was observed after 6 weeks (p<0.01), 12 weeks (p¼0.01), 30 weeks (p¼0.02) and 36 weeks (p¼0.02). Initial mean central macular thickness was 5296211 mm and a statistically significant decrease was observed after 6 weeks (p¼0.03), 24 weeks (p¼0.02), 30 weeks (p¼0.02) and 36 weeks (p¼0.02). Baseline BCVA and central retinal thickness were statistically different between BRVO and CRVO subgroups and no further comparisons were done between them.
Four patients (three with CRVO and one with BRVO) developed an ERM following the administration of intravitreal bevacizumab (figures 1e3). Characteristics of these patients are described in table 2.
Increase in central retinal thickness and deterioration of BCVA in one or more lines compared with baseline occurred in three cases (12%), one patient with BRVO and two patients with CRVO. This rebound was detected after 6 to 18 weeks from previous bevacizumab injection. One of these patients did not receive further therapy and no anatomical or functional improvement was observed during the following 12 weeks. The second patient showed an improvement of BCVA and a decrease in central macular thickness compared with baseline after being retreated. The third patient with rebound developed an ERM (case 1 in table 2).
No other ocular or systemic complications related to the use of intravitreal bevacizumab were observed during this study.
DISCUSSION
The results of the present study are congruent with several previous reports in which repeated intravitreal bevacizumab injections have been associated with short-term anatomical and functional improvement in patients with RVO, needing repeated injections to maintain this transient benefit in most of the patients.
3e6 Subgroup analysis showed significant improvement in BCVA and decrease of macular oedema in patients with CRVO treated with bevacizumab, but not in those with BRVO. We believe that the lack of benefit observed in the BRVO group may be related to the sample size.
Recurrence of macular oedema appears to be a frequent situation despite the use of fixed initial re-treatments and high rate of re-injections of bevacizumab. In our series, we observed not only recurrence of macular oedema, but also rebound of cystoid macular oedema with deterioration of visual acuity compared with baseline in 3 patients. In two of these eyes, retreatment with bevacizumab produced a new decrease in central macular thickness due to reabsorption of macular oedema and increase in BCVA.
Previous reports of intravitreal bevacizumab for RVO have described the reabsorption of macular oedema by measuring the central macular thickness with OCT, but few details regarding the qualitative changes of the macula have been given. It is known that OCT is a very useful tool for the diagnosis of ERM especially in cases where macular oedema and intraretinal haemorrhages may be difficult to diagnose by biomicroscopy. In our study, an incidence of 16% of secondary ERM was observed, similar to the 16.1% observed by the Blue Mountains Study in eyes with RVO. 9 Interestingly, there is no description in the literature of ERM growth in patients with RVO treated with bevacizumab despite the numerous studies recently published. One possible explanation for this situation may be that most of these studies focus on the description of quantitative changes of central macular thickness measured with OCT, but few data are given about the qualitative changes of the macula during follow-up. Due to the characteristics of our study it is difficult to determine a causeeeffect relationship between intravitreal bevacizumab and early development of secondary ERM, but there are some elements that allows us to establish this possibility. First, in an early report by Wise, 10 the development of 'preretinal folds' occurred between 6 and 12 months after the diagnosis of RVO. These folds are the tractional forces of the contracted ERM on the retinal surface. The growth and contraction of ERM is though to be a slow process, but in our study ERM rapidly appeared 6e7 weeks after the injection of bevacizumab in eyes with RVO diagnosed 5.5 to 12.5 months earlier. Another case with history of 44.5 months of CRVO developed a premacular membrane only 7 weeks after a second injection of bevacizumab, suggesting that this treatment might be related to this change in the evolution of the disease and the beginning of premacular proliferation. But how can bevacizumab participate in the development of ERM in eyes with RVO? The administration of an anti-VEGF therapy does not only block the pro-angiogenic stimulus of VEGF, but also changes the relation, expression and activity of numerous cytokines, growth factors and mediators present in the retinal tissue, retinal vessels and retinal surface. A rise in the levels of VEGF produces an increase in nitric oxide (NO) production by endothelial cells.
11 NO is involved in controlling retinal blood flow during hypoxia and constitutes one of the main pathways to stimulate endothelial cell proliferation and migration, release of proteases and increase in capillary permeability.
12e15 In an experimental model, Donati et al observed that a decrease in NO production causes an arteriolar constriction in eyes with BRVO, contributing to maintain the hypoxia. 16 It has been proposed that anti-VEGF therapy could reduce the capacity of the endothelium to produce NO. 11 Therefore, despite the anti-oedematous and anti-angiogenic role of bevacizumab, it could also produce an increase in retinal ischaemia by reducing NO production. Clinically, the transformation of a non-ischaemic CRVO into a ischaemic CRVO after intravitreal bevacizumab have been recently described. 8 Apart from VEGF there are some other factors like platelet-derived growth factor A and tumour necrosis factor-a that participate in the growth of ERMs. 17e19 An increase in such factors, as a consequence of persistent ischaemia, could explain the development of ERM in patients with RVO treated with bevacizumab. In our study, visual acuity remained stable in two of the patients with ERM after bevacizumab compared with baseline, while in the other two patients there was an improvement in vision. Even when ERM can limit visual recovery, vitrectomy and peeling of the membrane was not indicated, since ERM was not associated with further deterioration of visual acuity or metamorphopsia.
It is well known that in ischaemic retinopathies VEGF is upregulated while pigment epithelium-derived factor (PEDF), an angiostatic and neurotrophic factor, is decreased. 20 Therefore, the administration of an anti-VEGF agent produces an imbalance towards the effect of PEDF. In addition, PEDF production by retinal glial cells is increased under a marked hypoxic environment. 21 Enhanced expression and location of PEDF, as well as stimulation by transforming growing factor b (TGF-b), has been observed in progressive fibrotic pathologies. 22 It suggests that a relative increase in PEDF after intravitreal bevacizumab may promote fibrotic changes of ERM in eyes with retinal ischaemia. Hypoxia can also promote the expression of TGF-b in Müller cells, 23 and consequently the presence of connective tissue growth factor (CTGF), an important mediator of retinal fibrosis and development of ERM. 24 In other tissues VEGF has shown to inhibit the expression of CTGF in a complex mechanism in which is also involved TGF-b. 25 We hypothesise that the blockage of VEGF through bevacizumab may increase the relative effect of factors such as PEDF and CTGF. This may produce a rapid development of the fibrotic component of an early ERM. Fibrosis, contraction and wrinkling of the ERM make the presence of the epimacular tissue more evident, facilitating the diagnosis of previously undetected lesions.
In conclusion, bevacizumab appears as a symptomatic treatment for vaso-occlusive diseases since recurrence of macular oedema is a frequent situation, even after repeated injections. The early development of secondary ERM in eyes with RVO may constitute a secondary effect of intravitreal bevacizumab considering the time effect relationship observed in the present study and the theoretical basis that can explain this phenomenon. We describe different mechanisms that may promote the growth of ERM in eyes with RVO, as well as an increase in fibrosis and secondary contraction of epimacular tissue after intravitreal bevacizumab. Although intravitreal bevacizumab is emerging as one of the possible treatments in retinal venous disease, we encourage the cautious administration of this therapy until randomised masked clinical trials determine the safety and efficacy of this treatment. 
